Mitochon Pharmaceuticals

Mitochon Pharmaceuticals is a biotechnology company founded in 2014, focusing on developing drugs targeting mitochondria for the treatment of many serious diseases with unmet medical needs. Mitochon Pharmaceuticals' development programs primarily concentrate on neurodegenerative and neuromuscular diseases, including: Huntington's disease, multiple sclerosis/optic neuritis, Wolfram syndrome, epilepsy, traumatic brain injury (TBI), Duchenne muscular dystrophy (DMD), Alzheimer's disease, and Parkinson's disease.